NCT02317874View on ClinicalTrials.gov

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

April 1, 2019

Study Completion Date

May 3, 2022

Conditions

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Interventions

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Talazoparib

Given PO

Trial Locations (3)

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Carbone Cancer Center, Madison

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02317874 - Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | Biotech Hunter | Biotech Hunter